In a long-overdue appearance, Saurabh Jha, MD, radiologist in Philadelphia, makes his triumphant return to the show to pick apart the single-payer model idea as well as FDA regulatory processes, this time with a worthy adversary: Adam Gaffney, MD, MPH, pulmonary specialist and health policy researcher at Cambridge Health Alliance/Harvard Medical School. The conversation begins with discussion of a proposed federal single-payer system in America, why it could not be modeled after a successful system like that in England, why significant health disparities exist geographically within a single-payer system and whether such a system can provide the tools to address these disparities, and so much more. Then, the conversation swings to whether a health care system should be designed to afford high-priced novel therapies because of failure to regulate these prices, on what basis the FDA should approve drugs, and other points of discussion. Things get testy in this spirited back-and-forth banter and you won’t want to miss it.
N/A
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
